Testimonials

Text Size

Integrated Drug Development

Nonclinical Development

Drug Product Development

Regulatory Affairs Team

Clinical Development Consultants

Back

WANT TO KNOW MORE?

You don't need to take our word for it - this is what our clients say about us. If you have any observations or want to know more, simply contact us.

Over the past 10 years we have successfully developed a solid drug pipeline ranging from commercialized drug products to novel compounds. The new generation of dual-function drugs under development at Taiwan Liposome Company (TLC) has the potential for higher anti-tumor potency and lower toxicity. The success of Lipotecan® entering Phase 1 clinical trials is a critical milestone for TLC, demonstrating our ability to develop new small molecule drug candidates for cancer treatments. We are expecting more drug candidates to be developed through our proprietary drug discovery program in the near future. The expertise provided by Aptuit Consulting was invaluable to us as we navigated the U.S. regulatory environment.

Dr. Keelung Hong, CEO and Chairman of TLC

Text Size

Home

About Us